MSH2 and adrenal cortex carcinoma: As shown in Figure 4 (d), in the PFI survival analysis, high expression of MSH2 was associated with poorer prognosis in ACC, CESC, KICH, KIRP, LGG, LIHC, PAAD, and UCEC.